Follow The Filings

LGND Ligand Pharmaceuticals

Ligand Pharmaceuticals earnings company data as of 11:09 PM ET 11/17

History

1 period, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 29 Oct EPS 1.42 — —
Rev $77.2M $78.7M —

Insider trades

Open-market buys and sales by LGND's executives, directors and 10% owners in the last 12 months, from their Form 4s

All LGND insider trades
  • None no insider bought on the open market
  • $10.8M sold by 6 insiders outside a trading plan
  • $25.7M sold by 3 insiders under 10b5-1 plans
  1. Martine Zimmermann Director
    Sale
    $636K 2,000 shares at $318.17 53% of stake
    Traded Nov 12 Filed Nov 16
  2. John W. Kozarich Director
    Planned sale
    $163K 500 shares at $325.00 1.2% of stake
    Traded Nov 12 Filed Nov 16
  3. Jason Aryeh Director
    Sale
    $960K 3,000 shares at $320.05 2.8% of stake
    Traded Nov 10 Filed Nov 12
  4. Jason Aryeh Director
    Sale
    $90K 282 shares at $319.99 0.3% of stake
    Traded Nov 4 Filed Nov 6
  5. Andrew Reardon CLO & Secretary
    Planned sale
    $1.6M 5,000 shares at $313.22 14% of stake
    Traded Nov 2 Filed Nov 4
  6. Jason Aryeh Director
    Sale
    $676K 2,111 shares at $320.30 1.9% of stake
    Traded Oct 30–Nov 2 Filed Nov 3
  7. Andrew Reardon CLO & Secretary
    Planned sale
    $1.5M 5,000 shares at $304.07 14% of stake
    Traded Oct 2 Filed Oct 6
  8. Martine Zimmermann Director
    Sale
    $342K 1,200 shares at $285.00 24% of stake
    Traded Sep 10 Filed Sep 14
  9. Andrew Reardon CLO & Secretary
    Planned sale
    $1.4M 5,000 shares at $286.09 12% of stake
    Traded Sep 3 Filed Sep 8
  10. Octavio Espinoza CFO
    Planned sale
    $9.2M 31,641 shares at $292.07 53% of stake
    Traded Aug 12 Filed Aug 14
  11. Jason Haas Director
    Sale
    $2.1M 7,138 shares at $292.81 64% of stake
    Traded Aug 12 Filed Aug 14
  12. Andrew Reardon CLO & Secretary
    Planned sale
    $1.4M 5,000 shares at $288.99 11% of stake
    Traded Aug 3 Filed Aug 4
  13. Andrew Reardon CLO & Secretary
    Planned sale
    $1.6M 5,000 shares at $313.28 11% of stake
    Traded Jul 1 Filed Jul 6
  14. Stephen L. Sabba Director
    Sale
    $545K 2,145 shares at $254.00 6% of stake
    Traded Jun 16 Filed Jun 18
  15. Jason Haas Director
    Sale
    $1.7M 6,461 shares at $255.58 57% of stake
    Traded Jun 12 Filed Jun 15

Also filed in the last 12 months, not counted as buying or selling: 32 option exercises, 18 share withholdings for taxes, 16 stock grants, 4 other transactions, and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13D/A —
10-Q
8-K 2.02,9.01
8-K 7.01,8.01
8-K 7.01,9.01
8-K/A 9.01
SCHEDULE 13G —
10-Q
8-K 2.02,9.01
8-K 1.01,2.01,2.03,7.01,9.01
8-K 1.01,2.03,3.02,8.01,9.01
8-K 1.01,8.01,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf